Uli Hacksell
Styrelseordförande at Medivir AB
📍 Tampa, Florida, United States
Uli Hacksell is the Chairman of the Board at Medivir AB, bringing extensive experience from the pharmaceutical industry. He previously served as CEO of ACADIA Pharmaceuticals for 15 years, guiding the company through significant growth. He holds a Ph. D. in medicinal chemistry from Uppsala University and is an expert in drug development.
He successfully led ACADIA Pharmaceuticals in developing NUPLAZID, the first drug approved for psychosis in Parkinsons disease.
Read the full overview →Current Role
Styrelseordförande
Location
Tampa, Florida, United States
Personality Overview
Personality insights not availableWe need more social data to generate the DISC analysis and selling playbook. The professional details below are still available.
Priorities
Topics Uli cares about
Drug Development
His career has been dedicated to advancing new medicines from research to market, particularly in challenging therapeutic areas.
CNS Disorders
Possesses deep expertise in Central Nervous System disorders, having led the development of a breakthrough drug for Parkinson's disease psychosis at ACADIA Pharmaceuticals.
Career
Work history
Styrelseordförande
Medivir AB
In the press
Media appearances
No media yetWe could not find public media appearances for this person.
Education
Uli has no verified education history
Social presence
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.